Pfizer’s Vyndamax (tafamidis) franchise generated worldwide sales of $6.3 billion in 2025, reflecting 17% growth from 2024. This made it one of the company’s most valuable products and the best-selling drug in the ATTR-CM market.
In an industry built on blockbuster medicines, this is the type of growth investors prize, but also the success that places marketing practices under greater scrutiny.
When billions of dollars are at stake, how aggressively can pharmaceutical companies market their products before claims begin to outpace the evidence used to support them?
Last month, a German court ordered Pfizer to stop using the phrase “near complete stabilization” in promotional materials for tafamidis, finding that the statement was not supported by the drug’s own data and approved label.
The ruling came in a proceeding involving Bayer, which commercializes BridgeBio’s competing drug, Attruby (acoramidis), in Europe. It was not a judgment on the drug itself or its efficacy but on whether a specific promotional claim was adequately supported by evidence.
This distinction matters. Pharmaceutical companies are expected to market their products aggressively, particularly when competition is intensifying. But regulators and courts have long maintained that promotional claims must remain grounded in the evidence supporting medicine and the language approved by health authorities.
A familiar challenge for Pfizer
The German ruling is not comparable to some of the regulatory investigations that have shaped Pfizer in the last few years. Yet, it touches on a recurring challenge for one of the world’s largest pharmaceutical companies.
This is not the first time that questions over promotional practices have attracted scrutiny.
In 2004, Warner-Lambert, which Pfizer acquired in 2000, agreed to pay $430m to settle allegations that it flouted federal drug regulations by marketing Neurontin (gabapentin) for conditions for which it had not been approved to treat.
“This illegal and fraudulent promotion scheme corrupted the information process relied upon by doctors in their medical decision-making, thereby putting patients at risk,” said United States Attorney Michael Sullivan.
Five years later, Pfizer and its subsidiary Pharmacia & Upjohn Company Inc. agreed to pay $2.3 billion to resolve criminal and civil liability arising from the illegal promotion of several drugs. At the time, the US Department of Justice described the agreement as the largest healthcare fraud settlement in its history.
Prosecutors said the payments reflected the “size and seriousness” of Pfizer’s infringements. Tom Perrelli, the associate attorney general, said it was a victory for the public over “those who seek to earn a profit through fraud.”
Among the medicines linked to the scandal were the anti-psychotic drug Geodon (ziprasidone), as well as the antibiotic Zyvox (linezolid), and a treatment for epilepsy, known as Lyrica (pregabalin).
This track record illustrates why questions about promotional practices continue to attract attention whenever Pfizer’s marketing claims are challenged.
Why investors should pay attention to Pfizer’s headwinds
Pfizer is currently managing patent-expiry headwinds across parts of its portfolio while investing heavily in new growth areas such as oncology and metabolic disease.
In this environment, investor confidence depends not only on the company’s ability to develop and acquire promising medicines but also on how those medicines are marketed.
Investors often focus on clinical trial results, regulatory approvals and patent protection when assessing pharmaceutical companies, and those factors remain critical. Yet the durability of a franchise also depends on credibility. Doctors, patients, payers and regulators need confidence that promotional claims accurately reflect the evidence supporting a medicine.
That is why disputes over marketing language can matter far beyond the courtroom. They can shape perceptions of a company’s compliance culture and influence how regulators, healthcare professionals and investors view its broader business practices.
The significance of the German ruling is that a court concluded Pfizer once again used promotional language that was not supported by the evidence and the approved label before it. For a company selling one of the world’s most successful cardiovascular medicines, that is a finding that investors should take seriously.
